The following table summarizes restructuring, acquisition and related costs recorded in the accompanying consolidated statements of operations for the periods indicated (in thousands):


	Year Ended December 31,
	2025			2024		2023
2025 restructuring	$	14,021		$	—	$	—
2024 restructuring		5,698			10,486		—
2022 restructuring		—			—		8,961
2020 restructuring		(3,595	)		—		2,853
Total restructuring related charges		16,124			10,486		11,814
Acquisition and related charges		6,528			3,223		1,000
Total restructuring, acquisition and related costs	$	22,652		$	13,709	$	12,814

The Company initiated the 2025 restructuring program in the second quarter of 2025 in order to streamline operations and align with our long-term goals. The 2025 restructuring program includes measures to regionalize manufacturing operations to better serve its customers, expedite the closure of certain sites, streamline management structures, and implement cost-saving strategies in areas anticipated to have a minimal long-term impact on the Company's overall business performance. During year ended December 31, 2025, the Company recorded $14.0 million in severance, facility related and other charges in connection with the 2025 restructuring program. As of December 31, 2025, the Company had incurred cumulative costs of $14.0 million related to this restructuring program. The Company anticipates substantially completing the 2025 restructuring program by the end of 2026. Total restructuring charges related to this program are expected to be approximately $25.0 million.

The following table summarizes restructuring costs associated with the 2025 restructuring program by reportable segment (in thousands):


	Year Ended December 31,		Cumulative Costs as of
	2025		December 31, 2025
Automation Enabling Technologies	$	3,269	$	3,269
Medical Solutions		7,325		7,325
Unallocated costs		3,427		3,427
Total	$	14,021	$	14,021

As a result of the Company’s acquisitions and ongoing integration activities, the Company initiated the 2024 restructuring program in the first quarter of 2024 in order to reduce operating complexity. During the year ended December 31, 2025, the Company recorded $5.7 million in severance, facility related and other charges in connection with the 2024 restructuring program. As of December 31, 2025, the Company had incurred cumulative costs of $16.2 million related to this restructuring program. The Company anticipates substantially completing the 2024 restructuring program by the end of 2026 and expects to incur additional restructuring charges of $2.0 million to $3.0 million related to the 2024 restructuring program.

The following table summarizes restructuring costs associated with the 2024 restructuring program by reportable segment (in thousands):


	Year Ended December 31,				Cumulative Costs as of
	2025		2024		December 31, 2025
Automation Enabling Technologies	$	1,390	$	3,198	$	4,588
Medical Solutions		4,276		6,769		11,045
Unallocated costs		32		519		551
Total	$	5,698	$	10,486	$	16,184

As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2022 restructuring program in the third quarter of 2022. This program was focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program was focused on cost reduction actions to improve gross margins for the overall company. As of December 31, 2025, the Company had incurred cumulative costs of $10.4 million related to the 2022 restructuring program. The 2022 restructuring program was completed in the fourth quarter of 2023.

The following table summarizes restructuring costs associated with the 2022 restructuring program by reportable segment (in thousands):


	Year Ended December 31,		Cumulative Costs as of
	2023		December 31, 2025
Automation Enabling Technologies	$	6,771	$	8,129
Medical Solutions		1,359		1,415
Unallocated costs		831		831
Total	$	8,961	$	10,375

As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2020 restructuring program in the third quarter of 2020. This program was focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program was focused on cost reduction actions to improve gross margins for the overall company. As of December 31, 2025, the Company had incurred cumulative costs of $13.1 million related to the 2020 restructuring program. The 2020 restructuring program was completed in the fourth quarter of 2023. In January 2025, the Company sold a facility from the 2020 restructuring program and recorded a $3.6 million gain in the Company’s Automation Enabling Technologies segment.

The following table summarizes restructuring costs associated with the 2020 restructuring program by reportable segment (in thousands):


	Year Ended December 31,							Cumulative Costs as of
	2025			2024		2023		December 31, 2025
Automation Enabling Technologies	$	(3,595	)	$	—	$	2,853	$	10,232
Medical Solutions		—			—		—		2,716
Unallocated costs		—			—		—		173
Total	$	(3,595	)	$	—	$	2,853	$	13,121

The following table summarizes the accrual activities, by component, related to the Company’s restructuring programs recorded in the accompanying consolidated balance sheets (in thousands):


	Total			Employee Related			Facility Related			Facility Sale			Other
Balance at December 31, 2023	$	2,850		$	1,038		$	1,680		$	—		$	132
Restructuring charges		10,486			8,165			2,034			—			287
Cash payments		(5,898	)		(3,469	)		(2,007	)		—			(422	)
Non-cash write-offs and other adjustments		(687	)		(44	)		(646	)		—			3
Balance at December 31, 2024		6,751			5,690			1,061			—			—
Restructuring charges		16,124			15,562			2,891			(4,077	)		1,748
Cash payments		(8,595	)		(12,012	)		(633	)		5,537			(1,487	)
Non-cash write-offs and other adjustments(1)		(3,698	)		649			(2,626	)		(1,460	)		(261	)
Balance at December 31, 2025	$	10,582		$	9,889		$	693		$	—		$	—

(1)

Non-cash charges primarily related to accelerated depreciation on a facility.

Acquisition costs incurred in connection with business combinations, primarily including finders’ fees, legal, valuation and other professional or consulting fees, totaled $5.7 million, $3.5 million, and $1.0 million during 2025, 2024, and 2023, respectively. Acquisition related costs/(income) recognized under earn-out agreements in connection with acquisitions totaled $0.8 million, $(0.3) million, and zero during 2025, 2024, and 2023, respectively. A majority of the acquisition and related costs of $6.5 million for 2025 were not allocated to any of the reportable segments.